Meanwhile, RRM1 expression has been shown to be a powerful predictor of survival or chemotherapy susceptibility in patients with carcinomas, such as pancreatic cancer 23, advanced nasopharyngeal carcinoma 24, and gastric cancer 25, treated with adjuvant gemcitabine‐based chemotherapy. This evidence concerns the gene RRM1 and nasopharyngeal carcinoma.